Genfit reports Phase II NASH data

Genfit S.A. (Euronext:GNFT) said GFT505 missed the primary endpoint of the Phase IIb GOLDEN-505 trial to treat non-alcoholic steatohepatitis (NASH) according to the study's initial design. GFT505 met the endpoint after the company reanalyzed its data to account for baseline disease severity and trial site heterogeneity.

Genfit expects to start a Phase III trial of the dual peroxisome proliferation activated receptor (PPAR) alpha and delta agonist by YE15. Genfit lost EUR 2.25 to EUR 50.85 in Paris on Thursday; it reported the data after market close. Intercept Pharmaceuticals Inc. (NASDAQ:ICPT), which plans to begin a Phase III study this half of OCA obeticholic acid to treat NASH, gained $22.05 to $282.69 on Thursday. ...